Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
BioMarin Pharmaceutical Inc. - Common Stock
(NQ:
BMRN
)
57.50
+0.33 (+0.58%)
Streaming Delayed Price
Updated: 1:00 PM EDT, Jul 3, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about BioMarin Pharmaceutical Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) – An Undervalued Biotech Stock With Strong Fundamentals
June 26, 2025
BIOMARIN PHARMACEUTICAL (NASDAQ:BMRN) is an undervalued biotech stock with strong profitability, financial health, and growth potential, making it a candidate for value investors.
Via
Chartmill
2 Profitable Stocks for Long-Term Investors and 1 to Be Wary Of
June 26, 2025
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Via
StockStory
2 Reasons to Watch BMRN and 1 to Stay Cautious
June 23, 2025
Over the last six months, BioMarin Pharmaceutical’s shares have sunk to $55.23, producing a disappointing 16.7% loss while the S&P 500 was flat. This might have investors contemplating their next...
Via
StockStory
Topics
Stocks
Jim Cramer Is All Aboard Union Pacific, But Shows No Love For Orphan Drugs
June 12, 2025
Jim Cramer recommends Union Pacific but is "getting tired of the orphan drug model." Here's what the "Mad Money" host said.
Via
Benzinga
Earnings Scheduled For May 1, 2025
May 01, 2025
Via
Benzinga
Here Are All 6 Stocks I've Bought Through 5 Months of 2025
June 05, 2025
A volatile stock market represents an ideal opportunity for long-term investors to pounce.
Via
The Motley Fool
Topics
Stocks
1 Mid-Cap Stock with Exciting Potential and 2 to Avoid
June 05, 2025
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with...
Via
StockStory
BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) – An Undervalued Biotech Stock Worth Watching
June 04, 2025
BIOMARIN PHARMACEUTICAL (NASDAQ:BMRN) appears undervalued with strong profitability, financial health, and growth potential, making it a candidate for value investors.
Via
Chartmill
Top movers in Friday's after hours session
May 23, 2025
As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Via
Chartmill
Inozyme Stock Rockets 179% After BioMarin Agrees To Acquire The Company For $270M: Retail Sentiment Brightens
May 16, 2025
The deal's per-share price consideration implies an 182% premium to Inozyme’s closing price of $1.42 on Thursday.
Via
Stocktwits
BioMarin Bolsters Pipeline With $270 Million Inozyme Pharma Takeover
May 16, 2025
Inozyme Pharma is working on an enzyme replacement therapy for ENPP1 deficiency in children.
Via
Investor's Business Daily
BMRN Q1 Earnings Call: BioMarin Outperforms on Revenue and Expands Pipeline Progress
May 16, 2025
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 14.8% year on year to $745.1 million. The company expects the...
Via
StockStory
BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) – An Undervalued Biotech Stock Worth Watching
May 14, 2025
BIOMARIN PHARMACEUTICAL (NASDAQ:BMRN) is an undervalued biotech stock with strong profitability, solid financial health, and reasonable growth prospects, making it a candidate for value investors.
Via
Chartmill
1 Healthcare Stock with Competitive Advantages and 2 to Brush Off
May 09, 2025
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID...
Via
StockStory
Topics
Stocks
Q1 Earnings Recap: AbbVie (NYSE:ABBV) Tops Therapeutics Stocks
May 07, 2025
Let’s dig into the relative performance of AbbVie (NYSE:ABBV) and its peers as we unravel the now-completed Q1 therapeutics earnings season.
Via
StockStory
Topics
Artificial Intelligence
Therapeutics Stocks Q1 Results: Benchmarking Sarepta Therapeutics (NASDAQ:SRPT)
May 07, 2025
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q1, starting with Sarepta...
Via
StockStory
Topics
Artificial Intelligence
10 Analysts Assess Biomarin Pharmaceutical: What You Need To Know
May 05, 2025
Via
Benzinga
A Look Into Biomarin Pharmaceutical Inc's Price Over Earnings
May 02, 2025
Via
Benzinga
BioMarin Pharmaceutical (NASDAQ:BMRN) Beats Q1 Sales Targets
May 01, 2025
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 14.8% year on year to $745.1 million. The company expects the full year’s...
Via
StockStory
What To Expect From BioMarin Pharmaceutical’s (BMRN) Q1 Earnings
April 30, 2025
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting earnings tomorrow after the bell. Here’s what to look for.
Via
StockStory
Topics
Artificial Intelligence
World Trade
2 Cash-Producing Stocks with Exciting Potential and 1 to Question
April 27, 2025
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Via
StockStory
1 of Wall Street’s Favorite Stock Worth Your Attention and 2 to Question
April 22, 2025
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because...
Via
StockStory
BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) is an undervalued gem with solid fundamentals.
April 19, 2025
BIOMARIN PHARMACEUTICAL INC has caught the attention as a great value stock. NASDAQ:BMRN excels in profitability, solvency, and liquidity, all while being very reasonably priced.
Via
Chartmill
Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction
April 16, 2025
Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating...
Via
Benzinga
Topics
Government
Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks
April 16, 2025
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with AbbVie...
Via
StockStory
Topics
Artificial Intelligence
6 Stocks With Clear Price Dislocations That I Purchased During Wall Street's Historic Volatility
April 11, 2025
Though the stock market is still historically pricey, a few phenomenal bargains have cropped up.
Via
The Motley Fool
Topics
Government
Stocks
World Trade
Spotting Winners: United Therapeutics (NASDAQ:UTHR) And Therapeutics Stocks In Q4
April 07, 2025
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with United...
Via
StockStory
Topics
Artificial Intelligence
Q4 Earnings Outperformers: Amgen (NASDAQ:AMGN) And The Rest Of The Therapeutics Stocks
April 03, 2025
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with Amgen...
Via
StockStory
Topics
Artificial Intelligence
BioMarin Seeks Label Expansion For Palynziq After Positive Phase 3 Results In Adolescent Patients
April 02, 2025
BioMarin's Phase 3 trial shows Palynziq significantly reduces blood Phe in adolescents with PKU. The company plans a regulatory submission for label expansion.
Via
Benzinga
The Future of Healthcare: 10 Predictions For The Next Decade
March 27, 2025
The healthcare industry stands on the brink of a transformative decade, driven by rapid advancements in technology, shifting demographics, and evolving patient expectations. Over the next ten years, we...
Via
MarketMinute
Topics
Artificial Intelligence
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.